TAU targets drug-resistant ovarian tumors with nanotechnology
Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.
Now Prof. Dan Peer of Tel Aviv University‘s Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer’s Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU’s Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits.
The objective of Peer’s research is two-fold: to provide a specific target for anti-cancer drugs to increase their therapeutic benefits, and to reduce the toxic side effects of anti-cancer therapies. The study was published in February in the journal ACS Nano.
Why chemotherapy fails
According to Prof. Peer, traditional courses of chemotherapy are not an effective line of attack. Chemotherapy’s failing lies in the inability of the medicine to be absorbed and maintained within the tumor cell long enough to destroy it. In most cases, the chemotherapy drug is almost immediately ejected by the cancer cell, severely damaging the healthy organs that surround it, leaving the tumor cell intact.
But with their new therapy, Peer and his colleagues saw a 25-fold increase in tumor-accumulated medication and a dramatic dip in toxic accumulation in healthy organs. Tested on laboratory mice, the gagomer mechanism effects a change in drug-resistant tumor cells. Receptors on tumor cells recognize the sugar that encases the gagomer, allowing the binding gagomer to slowly release tiny particles of chemotherapy into the cancerous cell. As more and more drugs accumulate within the tumor cell, the cancer cells begin to die off within 24-48 hours.
“Tumors become resistant very quickly. Following the first, second, and third courses of chemotherapy, the tumors start pumping drugs out of the cells as a survival mechanism,” said Prof. Peer. “Most patients with tumor cells beyond the ovaries relapse and ultimately die due to the development of drug resistance. We wanted to create a safe drug-delivery system, which wouldn’t harm the body’s immune system or organs.”
The Latest on: Ovarian cancer
via Google News
The Latest on: Ovarian cancer
- 'Chicago Med' star Marlyne Barrett gets candid on ovarian cancer diagnosis, chemotherapyon September 29, 2022 at 3:50 pm
"Chicago Med" star Marlyne Barrett revealed Thursday she was diagnosed with ovarian cancer. She thanked fans and colleagues for their "support." ...
- MEDIA ADVISORY: Cedars Run for Ovarian Cancer - Walk & Run on October 16th To Raise Money for Women's Cancer Researchon September 29, 2022 at 7:50 am
MONTREAL, QC / ACCESSWIRE / / The 7th Annual Cedars Run for Ovarian Cancer will take place on Sunday, October 16th, 2022, in the Town of Mount-Royal. This signature event brings together friends, ...
- Ovarian cancer patient hopes to spread awareness and ‘paint’ Roanoke tealon September 29, 2022 at 7:12 am
Her name is Kim Huddleston and she hopes to ‘paint’ the town teal—the color worn to raise awareness about ovarian cancer. By wearing teal and sharing her story she hopes it will spark a conversation ...
- ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCSon September 29, 2022 at 5:00 am
Mirvetuximab Plus Bevacizumab Demonstrated Meaningful Efficacy in Recurrent FRα-Positive Ovarian Cancer Across a Broad Range of FRα Expression Regardless of Prior Treatment; Data to be Highlighted in ...
- Newlywed shares journey of battling ovarian cancer, how a team of doctors helped preserve her fertilityon September 29, 2022 at 3:59 am
She said her doctor helped make her miracle possible. “I have a love for Dr. Davis that I can’t explain,” Mavridis said. “She is an angel.” They have been through an experience that has bonded them ...
- 'Chicago Med' Star Marlyne Barrett Reveals She Has Uterine and Ovarian Canceron September 27, 2022 at 4:31 pm
Marlyne Barrett, who plays nurse Maggie Lockwood on "Chicago Med," tells People she has uterine and ovarian cancer.
- 20,000 women will be diagnosed with ovarian cancer in 2022. Here's how to protect yourselfon September 27, 2022 at 3:39 pm
In 2022, nearly 20,000 women in the U.S. are expected to receive an ovarian cancer diagnosis. And more than 12,000 (or 1 in 108) will die from it, according to the American Cancer Society.
- 'Chicago Med's Marlyne Barrett Diagnosed With Uterine and Ovarian Canceron September 27, 2022 at 2:44 pm
Chicago Med’s Marlyne Barrett revealed that she has been privately battling uterine and ovarian cancer. On Tuesday, the 44-year-old actress took to Instagram to share a picture of her freshly shaven ...
- Chicago Med 's Marlyne Barrett Shares Uterine, Ovarian Cancer Diagnosison September 27, 2022 at 12:53 pm
Marlyne Barrett, who plays a cancer survivor on Chicago Med, revealed that she has been battling cancer. Find out why she “felt a responsibility” to tell her story.
- Genes that increase breast and ovarian cancer riskson September 27, 2022 at 10:01 am
Many know October as breast cancer awareness month, but a special week is also set aside specifically to focus on hereditary breast and ovarian cancer.
via Bing News